Dimerix
(ASX:DXB)
Our Initial Entry
Price
Portfolio Initiation
5 Day VWAP
After Initiation
Current Price
Our Current Returns
ASX:DXB
$0.200
$0.400
Aug 16 2021
Aug 16 2021
$0.348
$0.155
-23%
|
ASX:DXB
|
Our Current Returns -23% |
Overview
What does DXB do?
DXB is an early stage biotech research company that is developing an anti-inflammatory drug to treat respiratory and kidney diseases, with potential applications to treat COVID.
What is the macro theme behind DXB?
Due to the pandemic, biotech and life sciences have been at the forefront of global decision making for investors, governments and ordinary consumers.
What was once an industry that was considered slow and niche is now rapidly evolving with innovation and technology.
Our Past Commentary on Dimerix
| Type | Date | Share Price $ | Title |
|---|---|---|---|
| 02-Sep-2022 | $ | Pre-result build up? The “big catalyst” in 2023 | |
| 01-Jun-2022 | $ | DXB Recruits First Patient, Gets FDA IND Approval | |
| 28-Feb-2022 | $ | DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused | |
| 01-Feb-2022 | $ | Earlier than Expected - DXB Gets First Regulatory Approval in Europe. | |
| Article | 21-Oct-2021 | $ | DXB kidney disease treatment Phase III trial officially begins |
| 15-Oct-2021 | $ | DXB to run a Phase III COVID-19 Study in Australia | |
| Article | 24-Sep-2021 | $ 0.300 | DXB announces approval for Phase III COVID-19 trials in India |
| 26-Aug-2021 | $ 0.320 | DXB kicks off Phase 3 clinical trials - Ethics approval lodged | |
| 16-Aug-2021 | $ 0.400 | The first investment in our new early stage, ASX listed biotech portfolio |